

## Monthly Market Commentary

Global equity markets started the calendar year strongly with supportive macro data helping broaden the rally away from US large caps. Against this backdrop, value, cyclicals and small caps all outperformed in January.

Japan's Nikkei225 was the standout amongst global indices, up 5.9% in local currency terms, and continuing its solid performance on growing odds of a strong election outcome for PM Sanae and her pro-growth agenda. Elsewhere in Asia, China's Shanghai Composite Index also delivered, finishing up 3.8% for the month.

US equities were stronger, aided in part by another decent reporting season. While large caps delivered reasonable performance with the NASDAQ and S&P500, up 0.9% and 1.37% respectively, it was small caps that stole the show with the S&P600 Small Cap Index up 5.5%. Large cap indices also lagged their equal-weighted equivalents with the S&P500 Equal-Weighted Index rising 3.28%, demonstrating broad-based strength.

In local currency terms, performance in Europe was more mixed. The UK FTSE outperformed most continental bourses, rising 2.9% for the month thanks to its outsized exposure to energy and materials. A disappointing result from software giant SAP weighed on Germany's DAX, though it still managed a 0.2% gain, while political uncertainty impacted sentiment towards France with the CAC40 falling 0.3%. That said, performance in USD terms across the board was a bit better courtesy of USD weakness with the DXY Index falling 1.4%.

At a sector level, performance was led by more economically sensitive areas exposed to capital spending cycles and commodity prices. Energy and Materials were strongest, rising 12.6% and 8.9%, respectively, with Industrials also up a solid 7.1%. Utilities, Telecommunications and Staples also did well, each up more than 3%. Financials, Health Care and Consumer Discretionary lagged in a relative sense, each up less than 1%. Information Technology was the worst performer, falling 1.2% in January, in part thanks to poorly received Q2 results from Microsoft and concerns around disruptions to many software companies' business models.

The AUD rose 4.4% against the USD, helped in part by broad-based commodity price strength. The Bloomberg Commodity Index finished up 10%, driven by precious metals with gold and silver up 13.3% and 18.8% in USD terms. Energy was also well supported with WTI oil prices up 13.6% for the month. VIX rose 2.49 points to close at 17.44, with yields on 10yr US Treasuries also rising 7bps to 4.24%.

Against this backdrop the Fund returned -1.02% for the month.

German-based Bayer was the biggest contributor to Fund performance with its shares performing strongly in the month following positive updates on the litigation front and drug development pipeline. US-based recruitment and consulting group, Robert Half, was also a meaningful contributor during the month with shares rising strongly on a well-received FY25 result that showed signs of sales stabilising. US-based HP Inc was the biggest detractor in January following a surge in memory chip prices, a key manufacturing component for the computer and printer maker.

During the month, the Fund gained exposure to Exor, a holding company controlled by one of Italy's wealthiest families, the Agnelli family. In addition to a significant stake in Ferrari, it also owns interests in agricultural and construction equipment maker CNH, automaker Stellantis, and health technology group Philips, along with a diverse range of other listed and unlisted investments. Additionally, the group has a solid balance sheet and has recently undertaken a share buyback equivalent to over 5% of the market cap. With the shares trading at over a 50% discount to Net Asset Value, we think Exor stock offers compelling value for shareholders.

We believe the most compelling way to compound clients' wealth is by utilising multiple return sources to deliver superior risk-adjusted investment outcomes.

- Long-term compounding of investor wealth
- Multiple sources of return
- Quarterly distributions
- Risk focused investment mindset



The investment process behind the Talaria Global Equity Fund Complex ETF takes a high conviction, value biased approach to construct a portfolio of high quality, large cap companies from around the globe. Our unique investment methodology harnesses the benefits of consistent income generation and capital appreciation to grow investors' real wealth.

## Performance as at 31 January 2026<sup>1</sup>

	1 Month	3 Months	6 Months	1 Year	3 Years (pa)	5 Years (pa)	7 Years (pa)	10 Years (pa)	Since Inception (pa) <sup>2</sup>
Total Return	-1.02%	1.59%	2.90%	3.93%	8.64%	10.81%	9.01%	8.30%	7.32%
Avg. Market Exposure <sup>4</sup>	56%	56%	58%	60%	60%	58%	58%	59%	61%

1 Fund Returns are calculated after fees and expenses and assume the reinvestment of distributions.

2 Inception date for performance calculation is 18 August 2008.

3 Past performance is not a reliable indicator of future performance.


4 Average Market Exposure calculated on delta-adjusted exposure of underlying portfolio. Since inception market exposure is calculated from September 2008.

## Growth of \$10,000 Since Inception<sup>5</sup>



5 Calculations are based on exit price, net of management fees and expenses and assumes reinvestment of distributions. Past performance is not a reliable indicator of future performance.

## Annual Distributions<sup>6</sup>



6 Illustrates Distribution Returns for the Talaria Global Equity Fund Complex ETF Units for the financial year ending 30 June 2025. Inception date is 18 August 2008.

## Talaria Asset Management

330 Collins Street  
 Melbourne, VIC, Australia 3000  
 info@talariacapital.com.au  
 talariacapital.com.au




## Top 10 Holdings<sup>7</sup>

Company Name	Holding	Country	Sector	Description
<b>Roche</b>	5.0%	Switzerland	Health Care	A global leader in cancer treatments
<b>EOG Resources</b>	4.9%	USA	Energy	One of North America's largest independent oil and gas producers
<b>Newmont</b>	4.9%	USA	Materials	One of the top 3 gold producers in the world
<b>Bayer</b>	4.7%	Germany	Health Care	Multinational pharmaceutical and life sciences company
<b>Essity</b>	4.6%	Sweden	Consumer Staples	A global health and hygiene company based in Sweden
<b>GSK</b>	4.4%	United Kingdom	Health Care	One of the world's largest pharmaceutical companies
<b>Bunzl</b>	4.3%	United Kingdom	Industrials	Multinational distribution and outsourcing business
<b>Everest Group</b>	4.2%	USA	Financials	Leading global provider of reinsurance and insurance services
<b>CF Industries</b>	3.7%	USA	Materials	North America's largest manufacturer of nitrogen-based fertiliser
<b>Chubb</b>	3.5%	USA	Financials	Global property and casualty insurance company


7 Weightings include option positions held and cash backing put options. It assumes that put options will be exercised.

Should the put option not be exercised the cash will revert to the unencumbered cash portfolio or may be used to cover further put options.

## Sector Allocation<sup>8</sup>



## Regional Allocation<sup>9</sup>



8,9 Weightings include option positions held and cash backing put options. It assumes that put options will be exercised. Should the put option not be exercised the cash will revert to the unencumbered cash portfolio or may be used to cover further put options.

\* USA includes American Depository Receipts (ADRs) listings.

## Fund Snapshot

<b>APIR Code</b>	AUS0035AU	<b>Inception Date</b>	18 August 2008
<b>Management Fee</b>	1.16% p.a. of the net asset value of the Fund plus Recoverable Expenses	<b>Liquidity</b>	Daily
<b>Recoverable Expenses</b>	Estimated to be 0.12% of net asset value of the Fund each Financial Year	<b>Exit Price</b>	\$4.83580 (31 Jan 2026)
		<b>Buy / Sell Spread</b>	0.20% / 0.20%
<b>Major Platform Availability</b>	Asgard, Ausmaq, BT Panorama, BT Wrap, CFS Edge, CFS FirstChoice, Dash, Expand, Hub24, IconiQ, IOOF Pursuit, Linear, Macquarie, Mason Stevens, Netwealth, North, Powerwrap, Praemium	<b>Distributions</b>	Quarterly
		<b>Minimum Investment</b>	\$5,000

## Important Information

Equity Trustees Limited ("Equity Trustees") (ABN 46 004 031 298), AFSL 240975, is the Responsible Entity for the Talaria Global Equity Fund Complex ETF ("the Fund"). Equity Trustees is a subsidiary of EQT Holdings Limited (ABN 22 607 977 615), a publicly listed company on the Australian Securities Exchange (ASX: EQT). This report has been prepared by Talaria Asset Management (Talaria) to provide you with general information only. In preparing this information, we did not take into account the investment objectives, financial situation or particular needs of any particular person. It is not intended to take the place of professional advice and you should not take action on specific issues without advice or information. Neither Talaria, Equity Trustees nor any of their related parties, their employees or contractors accept any liability for any loss or damage that may result from your use of this report. Past performance is not indicative of future performance. The Target Market Determination is available here. A Target Market Determination is a document which is required to be made available from 5 October 2021. It describes who this financial product is likely to be appropriate for (i.e. the target market), and any conditions around how the product can be distributed to investors. It also describes the events or circumstances where the Target Market Determination for this financial product may need to be reviewed. The Zenith Investment Partners (ABN 27 103 132 672, AFSL Licence 224872) ("Zenith") rating (assigned November 2025 for fund AUS0035AU) referred to in this page is limited to "General Advice" ("s766B Corporations Act 2001) for wholesale clients only. This advice has been prepared without taking into account the objectives, financial situation or needs of any individual, including target markets of financial products, where applicable, and is subject to change at any time without prior notice. It is not a specific recommendation to purchase, sell or hold the relevant product(s). Investors should seek independent financial advice before making an investment decision and should consider the appropriateness of this advice in light of their own objectives, financial situation and needs. Investors should obtain a copy of, and consider the PDS or offer document before making any decision and refer to the full Zenith Product Assessment available on the Zenith website. Past performance is not an indication of future performance. Zenith usually charges the product issuer, fund manager or related party to conduct Product Assessments. Full details regarding Zenith's methodology, ratings definitions and regulatory compliance are available on our Product Assessments and at Fund Research Regulatory Guidelines. The rating issued 04/2023 is published by Lonssec Research Pty Ltd ABN 11 151 658 561 AFSL 421445 (Lonssec). Ratings are general advice only, and have been prepared without taking account of your objectives, financial situation or needs. Consider your personal circumstances, read the product disclosure statement and seek independent financial advice before investing. The rating is not a recommendation to purchase, sell or hold any product. Past performance information is not indicative of future performance. Ratings are subject to change without notice and Lonssec assumes no obligation to update. Lonssec uses objective criteria and receives a fee from the Fund Manager. Visit lonssec.com.au for ratings information and to access the full report. © 2025 Lonssec. All rights reserved. The Genium rating (assigned May 2025) presented in this document is issued by Genium Investment Partners Pty Ltd ABN 13 099 785, which is a Corporate Authorised Representative of Genium Services Pty Ltd ABN 94 304 403 582, AFSL 246580. The Rating is limited to "General Advice" ("s766B Corporations Act 2001 (Cth)") and has been prepared without taking into account the objectives, financial situation or needs of any individual, including target markets of financial products, where applicable, and is subject to change at any time without notice. Past performance information is for illustrative purposes only and is not indicative of future performance. It is not a recommendation to purchase, sell or hold the relevant product(s). Investors should seek independent financial advice before making an investment decision in relation to this financial product(s). Genium receives a fee from the Fund Manager for researching and rating the product(s). Visit Genium.com.au for information regarding Genium's Ratings methodology. The Global Industry Classification Standard ("GICS") was developed by and is the exclusive property and a service mark of MSCI Inc. ("MSCI") and Standard & Poor's, a division of The McGraw-Hill Companies, Inc. ("S&P") and is licensed for use by Talaria Asset Management. Neither MSCI, S&P nor any third party involved in making or compiling the GICS or any GICS classifications makes any express or implied warranties or representations with respect to such standard or classification (or the results to be obtained by the use thereof), and all such parties hereby expressly disclaim all warranties of originality, accuracy, completeness, merchantability and fitness for a particular purpose with respect to any of such standard or classification. Without limiting any of the foregoing, in no event shall MSCI, S&P, any of their affiliates or any third party involved in making or compiling the GICS or any GICS classifications have any liability for any direct, indirect, special, consequential or any other damages (including lost profits) even if notified of the possibility of such damages.

Signatory of:

